Caner Civan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Caner Civan has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Duygu Has Simsek
Istanbul Faculty of Medicine, Department of Nuclear Medicine, Istanbul University, Istanbul, Turkey
8 shared publications - Serkan Kuyumcu
Istanbul Faculty of Medicine, Department of Nuclear Medicine, Istanbul University, Istanbul, Turkey
8 shared publications Duygu Has Simsek
Istanbul University Istanbul Faculty of Medicine
6 shared publicationsEmine Goknur Isik
From the Department of Nuclear Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
6 shared publications- Emine Goknur Isik
Department of Nuclear Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
5 shared publications Serkan Kuyumcu
From the Department of Nuclear Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
5 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by Elsevier in European Urology Focus
- Vol. 12 (5) , 939-947
PSMA-PET Tumor Volume Stratifies Nonmetastatic Castration-resistant Prostate Cancer
- 9 September 2026
- Published by Elsevier in European Urology Focus
- Vol. 12 (5) , 939-947
Open AccessPSMA-PET Tumor Volume Stratifies Nonmetastatic Castration-resistant Prostate Cancer
- 24 August 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (13) , 8386-8393
Outcomes of [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide in metastatic castration-resistant prostate cancer: a single-center retrospective study
Purpose Concurrent enzalutamide may upregulate PSMA expression and enhance the efficacy of [177Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT). We evaluated outcomes of PSMA-RLT with and without concurrent enzalutamide in a real-world metastatic castration-resistant prostate cancer (mCRPC) cohort. Methods We retrospectively evaluated 208 mCRPC patients treated with [177Lu]Lu-PSMA-617 at a single institution between June 2015 and January 2026. Among them, 106 received concurrent enzalutamide and 102 without any concurrent androgen receptor pathway inhibitor. The primary endpoint was overall survival (OS), and secondary endpoints were progression-free survival (PFS), PSA50 response, pain response, and toxicity. Results Median OS was 20.0 months in the concurrent enzalutamide group versus 12.4 months in the no-ARPI group (log-rank p = 0.082). In multivariable Cox analysis, concurrent enzalutamide was not independently associated with OS (hazard ratio 1.15, 95% confidence interval 0.77–1.70; p = 0.493). This lack of independent association was confirmed in propensity-score adjusted analyses. PFS (7.1 vs. 6.1 months; p = 0.112), PSA50 response rates (57.5% vs. 47.1%; p = 0.130) and toxicity profiles were similar between groups. Conclusion Concurrent enzalutamide during PSMA-RLT was not independently associated with improved OS or PFS in our cohort. The combination did not result in increased toxicity. Prospective studies are needed to further clarify the role of concurrent enzalutamide in this setting.
- 24 August 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (13) , 8386-8393
Outcomes of [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide in metastatic castration-resistant prostate cancer: a single-center retrospective study
Purpose Concurrent enzalutamide may upregulate PSMA expression and enhance the efficacy of [177Lu]Lu-PSMA-617 radioligand therapy (PSMA-RLT). We evaluated outcomes of PSMA-RLT with and without concurrent enzalutamide in a real-world metastatic castration-resistant prostate cancer (mCRPC) cohort. Methods We retrospectively evaluated 208 mCRPC patients treated with [177Lu]Lu-PSMA-617 at a single institution between June 2015 and January 2026. Among them, 106 received concurrent enzalutamide and 102 without any concurrent androgen receptor pathway inhibitor. The primary endpoint was overall survival (OS), and secondary endpoints were progression-free survival (PFS), PSA50 response, pain response, and toxicity. Results Median OS was 20.0 months in the concurrent enzalutamide group versus 12.4 months in the no-ARPI group (log-rank p = 0.082). In multivariable Cox analysis, concurrent enzalutamide was not independently associated with OS (hazard ratio 1.15, 95% confidence interval 0.77–1.70; p = 0.493). This lack of independent association was confirmed in propensity-score adjusted analyses. PFS (7.1 vs. 6.1 months; p = 0.112), PSA50 response rates (57.5% vs. 47.1%; p = 0.130) and toxicity profiles were similar between groups. Conclusion Concurrent enzalutamide during PSMA-RLT was not independently associated with improved OS or PFS in our cohort. The combination did not result in increased toxicity. Prospective studies are needed to further clarify the role of concurrent enzalutamide in this setting.
- Open Access
- 25 December 2025
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 56 (2) , 229-234
The value of PSMA PET for risk stratification in prostate cancer: an update and future aspects
- 25 December 2025
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 56 (2) , 229-234
Open AccessThe value of PSMA PET for risk stratification in prostate cancer: an update and future aspects
- Open Access
- 13 December 2025
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 56 (1) , 9-17
Treatment response assessment according to updated PROMISE criteria
- 13 December 2025
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 56 (1) , 9-17
Open AccessTreatment response assessment according to updated PROMISE criteria
- 12 June 2025
- Published by Elsevier in Seminars in Radiation Oncology
- Vol. 35 (3) , 463-473
Radiopharmaceuticals in Prostate Cancer: General Considerations and Utility in Combination With EBRT
- 12 June 2025
- Published by Elsevier in Seminars in Radiation Oncology
- Vol. 35 (3) , 463-473
Radiopharmaceuticals in Prostate Cancer: General Considerations and Utility in Combination With EBRT
- 26 June 2024
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 39 (5) , 373-380
The Role of [ 18 F]FDG PET/CT in the Characterization of Thymic Epithelial Tumors at Initial Stage
Purpose: The aim of this study was to evaluate the potential role of [ 18 F]FDG positron emission tomography/computed tomography (PET/CT) in the characterization of thymic epithelial tumors (TETs). Materials and Methods: A total of 73 patients who underwent preoperative [ 18 F]FDG PET/CT were included in this study. Visual total score (VTS), maximum standard uptake values (SUV max ), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and heterogeneity index (HI) parameters were analyzed to investigate the prediction of histopathologic grade and advanced stage. Results: The cohort included 26 patients with low-grade thymoma (LGT), 36 patients with high-grade thymoma (HGT), and 11 patients with thymic carcinoma (TC). Ninety-one percent of TC had VTS >2, whereas 31% of LGT and 75% of HGT had VTS >2. SUV max , MTV, and TLG were statistically significantly higher in the TC group than in both thymoma and HGT. Using the cutoff value of 7.25 for SUV max , TC was differentiated from thymomas with 91% sensitivity and 74% specificity. TC had significantly lower HI values than thymomas. HI parameters showed good diagnostic ability to differentiate TC from thymoma and TC from HGT. SUV max , MTV, and TLG were significantly higher in advanced-stage disease than in early-stage disease. Conclusions: Visual and quantitative parameters can reliably predict both advanced disease and the grade of primary tumor in TETs. Therefore, as a promising metabolic imaging method, [ 18 F]FDG PET/CT makes important contributions to preoperative evaluation in routine clinical practice.
- 26 June 2024
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 39 (5) , 373-380
The Role of [ 18 F]FDG PET/CT in the Characterization of Thymic Epithelial Tumors at Initial Stage
Purpose: The aim of this study was to evaluate the potential role of [ 18 F]FDG positron emission tomography/computed tomography (PET/CT) in the characterization of thymic epithelial tumors (TETs). Materials and Methods: A total of 73 patients who underwent preoperative [ 18 F]FDG PET/CT were included in this study. Visual total score (VTS), maximum standard uptake values (SUV max ), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and heterogeneity index (HI) parameters were analyzed to investigate the prediction of histopathologic grade and advanced stage. Results: The cohort included 26 patients with low-grade thymoma (LGT), 36 patients with high-grade thymoma (HGT), and 11 patients with thymic carcinoma (TC). Ninety-one percent of TC had VTS >2, whereas 31% of LGT and 75% of HGT had VTS >2. SUV max , MTV, and TLG were statistically significantly higher in the TC group than in both thymoma and HGT. Using the cutoff value of 7.25 for SUV max , TC was differentiated from thymomas with 91% sensitivity and 74% specificity. TC had significantly lower HI values than thymomas. HI parameters showed good diagnostic ability to differentiate TC from thymoma and TC from HGT. SUV max , MTV, and TLG were significantly higher in advanced-stage disease than in early-stage disease. Conclusions: Visual and quantitative parameters can reliably predict both advanced disease and the grade of primary tumor in TETs. Therefore, as a promising metabolic imaging method, [ 18 F]FDG PET/CT makes important contributions to preoperative evaluation in routine clinical practice.
- 26 June 2024
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 39 (5) , 330-336
Influence of Early Versus Delayed Hepatic Artery Perfusion Scan on 90 Y Selective Internal Radiation Therapy Planning
Purpose: This study evaluated the effect of an increase in the time interval between hepatic intra-arterial injection of 99m Tc-macroaggregated albumin (MAA) and hepatic artery perfusion scintigraphy (HAPS) on the lung shunt fraction (LSF) and perfused volume (PV) calculations in the treatment planning of selective internal radiation therapy (SIRT). Methods: The authors enrolled 51 HAPS sessions from 40 patients diagnosed with primary or metastatic liver malignancy. All patients underwent scan at the first and fourth hour after hepatic arterial injection of 99m Tc-MAA. Based on single-photon emission computed tomography images, LSF values were measured from each patient's first and fourth hour images. PV1 and PV4 were also calculated based on three-dimensional images using 5% and 10% cutoff threshold values and compared with each other. Results: The authors found that the median of LSF4 was statistically significantly higher than LSF1 (3.05 vs. 4.14, p ≤ 0.01). There was no statistically significant difference between PV1 and PV4 on the 10% ( p = 0.72) thresholds. Conclusions: LSF values can be overestimated in case of delayed HAPS, potentially leading to treatment cancellation due to incorrectly high results in patients who could benefit from SIRT. Threshold-based PV values do not significantly change over time; nevertheless, keeping the short interval time would be safer.
- 26 June 2024
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 39 (5) , 330-336
Influence of Early Versus Delayed Hepatic Artery Perfusion Scan on 90 Y Selective Internal Radiation Therapy Planning
Purpose: This study evaluated the effect of an increase in the time interval between hepatic intra-arterial injection of 99m Tc-macroaggregated albumin (MAA) and hepatic artery perfusion scintigraphy (HAPS) on the lung shunt fraction (LSF) and perfused volume (PV) calculations in the treatment planning of selective internal radiation therapy (SIRT). Methods: The authors enrolled 51 HAPS sessions from 40 patients diagnosed with primary or metastatic liver malignancy. All patients underwent scan at the first and fourth hour after hepatic arterial injection of 99m Tc-MAA. Based on single-photon emission computed tomography images, LSF values were measured from each patient's first and fourth hour images. PV1 and PV4 were also calculated based on three-dimensional images using 5% and 10% cutoff threshold values and compared with each other. Results: The authors found that the median of LSF4 was statistically significantly higher than LSF1 (3.05 vs. 4.14, p ≤ 0.01). There was no statistically significant difference between PV1 and PV4 on the 10% ( p = 0.72) thresholds. Conclusions: LSF values can be overestimated in case of delayed HAPS, potentially leading to treatment cancellation due to incorrectly high results in patients who could benefit from SIRT. Threshold-based PV values do not significantly change over time; nevertheless, keeping the short interval time would be safer.
- Open Access
- 19 February 2024
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 33 (2) , 109-111
Diagnosis and Evaluation of Treatment Response in Relapsing Polychondritis Using 18F-FDG PET/CT
Diagnosis and Evaluation of Treatment Response in Relapsing Polychondritis Using 18F-FDG PET/CT - Molecular Imaging and Radionuclide Therapy
- 19 February 2024
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 33 (2) , 109-111
Open AccessDiagnosis and Evaluation of Treatment Response in Relapsing Polychondritis Using 18F-FDG PET/CT
Diagnosis and Evaluation of Treatment Response in Relapsing Polychondritis Using 18F-FDG PET/CT - Molecular Imaging and Radionuclide Therapy
- Open Access
- 19 February 2024
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 33 (2) , 125-128
18F-FDG and 68Ga-FAPI-04 PET/CT Findings of a Rare Epithelialmyoepithelial Carcinoma Arising From Ex Pleomorphic Adenoma of Parotid
18F-FDG and 68Ga-FAPI-04 PET/CT Findings of a Rare Epithelial-myoepithelial Carcinoma Arising From Ex Pleomorphic Adenoma of Parotid - Molecular Imaging and Radionuclide Therapy
- 19 February 2024
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 33 (2) , 125-128
Open Access18F-FDG and 68Ga-FAPI-04 PET/CT Findings of a Rare Epithelialmyoepithelial Carcinoma Arising From Ex Pleomorphic Adenoma of Parotid
18F-FDG and 68Ga-FAPI-04 PET/CT Findings of a Rare Epithelial-myoepithelial Carcinoma Arising From Ex Pleomorphic Adenoma of Parotid - Molecular Imaging and Radionuclide Therapy
- Open Access
- 30 January 2024
- Published by Wiley
Locoregional treatment of fibrolamellar hepatocellular carcinoma in a child patient: a case report
Transarterial radioembolization (TARE) with Yttrium-90- microspheres is a well-tolerated and efficient treatment option in adult patients with unresectable primary and secondary liver malignancies. However, the use of TARE has been reported in limited pediatric cases. We present a twelve-year-old male with metastatic unresectable fibrolamellar hepatocellular carcinoma who received multidisciplinary treatments including chemotherapy, TARE, and transarterial chemoembolization with remarkable regression of the hepatic lesions. The patient is alive with the disease and a good quality of life for 33 months since diagnosis.
- 30 January 2024
- Published by Wiley
Open AccessLocoregional treatment of fibrolamellar hepatocellular carcinoma in a child patient: a case report
Transarterial radioembolization (TARE) with Yttrium-90- microspheres is a well-tolerated and efficient treatment option in adult patients with unresectable primary and secondary liver malignancies. However, the use of TARE has been reported in limited pediatric cases. We present a twelve-year-old male with metastatic unresectable fibrolamellar hepatocellular carcinoma who received multidisciplinary treatments including chemotherapy, TARE, and transarterial chemoembolization with remarkable regression of the hepatic lesions. The patient is alive with the disease and a good quality of life for 33 months since diagnosis.